Jade Biosciences (JBIO) Free Cash Flow (2020 - 2026)
Jade Biosciences posted quarterly Free Cash Flow of -$24.1 million for Q1 2026, down 28.45% year-on-year from -$33.7 million in Q1 2025, and up 28.47% on a QoQ basis from -$33.7 million in Q4 2025.
Jade Biosciences (JBIO) has 7 years of Free Cash Flow data on file, last reported at -$24.1 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 28.45% year-over-year to -$24.1 million; the trailing twelve-month figure through Mar 2026 stood at -$100.2 million (down 108.03% YoY), and the FY2025 full-year result was -$94.9 million, down 33.27% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$24.1 million, up from -$33.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$5.7 million in Q1 2022 and bottomed at -$33.7 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$15.3 million (2022), against an average of -$16.8 million.
- The widest annual swing landed in 2024, when Free Cash Flow surged 56.48%; it then sank 227.51% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$15.0 million in 2022, then rose by 0.98% to -$14.9 million in 2023, then slumped by 52.0% to -$22.6 million in 2024, then slumped by 48.99% to -$33.7 million in 2025, then advanced by 28.47% to -$24.1 million in 2026.
- The last three Free Cash Flow figures came in at -$24.1 million (Q1 2026), -$33.7 million (Q4 2025), and -$22.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | -24.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.10 Mn |
| Mar 31, 2026 | -24.10 Mn |
| Dec 31, 2025 | -33.69 Mn |
| Dec 31, 2025 | -33.69 Mn |
| Sep 30, 2025 | -22.28 Mn |
| Sep 30, 2025 | -22.28 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -22.61 Mn |
| Dec 31, 2024 | -22.61 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Mar 31, 2024 | -23.67 Mn |
| Mar 31, 2024 | -23.67 Mn |
| Dec 31, 2023 | -14.88 Mn |
| Dec 31, 2023 | -14.88 Mn |
| Sep 30, 2023 | -15.63 Mn |
| Sep 30, 2023 | -15.63 Mn |
| Jun 30, 2023 | -14.96 Mn |
| Jun 30, 2023 | -14.96 Mn |
| Mar 31, 2023 | -11.45 Mn |
| Mar 31, 2023 | -11.45 Mn |
| Dec 31, 2022 | -15.03 Mn |
| Dec 31, 2022 | -15.03 Mn |
| Sep 30, 2022 | -9.60 Mn |
| Sep 30, 2022 | -9.60 Mn |
| Jun 30, 2022 | -8.95 Mn |
| Jun 30, 2022 | -8.95 Mn |
| Mar 31, 2022 | -5.75 Mn |
| Mar 31, 2022 | -5.75 Mn |
| Dec 31, 2021 | -13.24 Mn |
| Dec 31, 2021 | -13.24 Mn |
| Sep 30, 2021 | -6.52 Mn |
| Sep 30, 2021 | -6.52 Mn |
| Jun 30, 2021 | -4.01 Mn |
| Jun 30, 2021 | -4.01 Mn |
| Mar 31, 2021 | -3.82 Mn |
| Mar 31, 2021 | -3.82 Mn |
| Dec 31, 2020 | -2.88 Mn |
| Dec 31, 2020 | -2.88 Mn |
| Sep 30, 2020 | -2.43 Mn |
| Sep 30, 2020 | -2.43 Mn |